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here is a wide variability in the forms of presentation of
heumatoid arthritis (RA). The age of onset of this disease
eems to be a critical factor in its clinical spectrum.1 It is
onsidered that a patient suffers elderly onset rheumatoid
rthritis (EORA) when the disease began at the age of ≥60
ears.1,2 This form of RA contributes with 10–33% of cases of
isease.3
The prevalence of RA increases with age and is estimated
o occur in up to 2.2% of the population >55 years.4 The genetic
nﬂuence, especially of HLA class 2 genes,5,6 acts not only in
he incidence rate, according to the age of onset,4,7,8 but also in
romoting the appearance of clinical peculiarities in each age
roup.9 Individuals with disease onset at a younger age have a
igher prevalence of HLA DRB1*04; in those with a late onset,
LA DRB1*01 prevails.8 On the other hand, elderly patients
ith the seronegative, polymyalgia-like form show increasing
revalence of HLA DRB1*13/*14.10Please cite this article in press as: Horiuchi AC, et al. Rheumatoid a
http://dx.doi.org/10.1016/j.rbre.2015.06.002
In contrast to the disease beginning in young individ-
als (young onset rheumatoid arthritis, or YORA), EORA seem
o follow a more  acute course, in association with systemic
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icenses/by-nc-nd/4.0/).phenomena such as fever, fatigue and weight loss, as well as
with the involvement of larger joints and higher prevalence
of atypical forms of onset as RS3PE (remitting seronegative
symmetrical synovitis with pitting edema) and polymyalgia
rheumatica-like forms.1 However, the statement that, with
increasing age, the prognosis becomes more  severe or even
that there are differences in the course of the disease for young
and elderly people, as some authors claim,1,4,5,11 is a contro-
versial matter, since the literature is not unanimous on this
point.5,8,11 A Brazilian study could not detect differences in
prognosis for both groups.6
The treatment of EORA patients pursuits the same goals
as those of YORA patients, i.e. to control the clinical mani-
festations, prevent structural damage, preserve function and
autonomy of the individual, and also prevent excess mortal-
ity caused by the disease.1 But some authors have observed
that the treatment of elderly patients is carried out differently,
with less aggressiveness opposed to that for YORA patients.2,4rthritis in elderly and young patients. Rev Bras Reumatol. 2016.
disease drugs in more  vulnerable people, with greater
possibility of drug interaction due to multiple co-morbidities
to which the elderly individual is usually subject.2,3
e under the CC BY-NC-ND license (http://creativecommons.org/
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Table 1 – Comparison of demographic, clinical and serological data between patients with elderly onset rheumatoid
arthritis (EORA) and young onset rheumatoid arthritis (YORA).
EORA
n  = 62
YORA
n  = 111
p
Gender (male/female) 14/48 11/100 0.02
Tobacco exposure (current smokers and
former smokers)
34/60  (56.5%) 52/110 (47.2%) 0.24
Racea (African descent/Caucasian) 14/62 32/100 0.19
Rheumatoid nodules 3/54 (5.5%) 5/106 (4.7%) 1.00
Interstitial pneumonitisb 7/51 (13.7%) 4/91 (4.3%) 0.056
DAS-28 1–6.7
Mean = 3.45 ± 1.49
1–7.2
Mean = 3.69 ± 1.56
0.39
Health Assessment Questionnaire (HAQ) 0–3
Median = 1
IQR = 0.12–1.62
0–2.75
Median = 1.43
IQR = 0.62–2.00
0.04
Presence of rheumatoid factor (RF) 49/62 (79.0%) 61/104 (58.6%) 0.007
Presence of antinuclear antibodies (ANA) 16/58 (27.5%) 41/104 (39.0%) 0.13
Association with hypothyroidism 7/56 (12.5%) 22/106 (20.7%) 0.19a According to the patient’s self-declaration.
b Found by high-resolution CT of the chest.
With increasing longevity and growth of the population
over 60 years, it is important to recognize the characteristics
of the local population with EORA to improve the quality of
health care offered to these patients. In this study, we sought
to evaluate the demographic, clinical, serological and treat-
ment proﬁles of the local population with EORA compared to
patients with YORA.
Patients  and  methods
This is a study approved by the Research Ethics Commit-
tee. RA patients who  met  at least four of the classiﬁcation
criteria of the American College of Rheumatology (1987) for
RA12 and being diagnosed with EORA1 who attended to a
single rheumatology outpatient clinic of a tertiary care cen-
ter during the period of one year (August 2012 to August
2013) were studied. This is an observational, analytical, cross-
sectional study of a convenience sample where patients with
EORA (n = 62) and with YORA (n = 111) properly matched for
disease duration were compared. Data about demographics,
presence of nodules, extra-articular manifestations of RA, the
presence of autoantibodies as rheumatoid factor (RF) and
antinuclear antibody (ANA), and use of medications were
obtained retrospectively through a review of their medical
records. Inﬂammatory activity indexes such as DAS (Disease
Activity Score) 2813 and of functional capacity measured by
HAQ (Health Assessment Questionnaire)14 were obtained dur-
ing the study period.
Data were gathered in frequency and contingency tables;
Chi-squared and Fischer tests were used for comparison of
nominal data; and Mann–Whitney and non-paired t tests
were applied to numerical data. The sample distribution was
studied by D’Agostino and Person test. Measures of central
tendency were expressed as mean and standard deviation
for Gaussian variables; and as median and interquartilePlease cite this article in press as: Horiuchi AC, et al. Rheumatoid a
http://dx.doi.org/10.1016/j.rbre.2015.06.002
range (IQR) for non-Gaussian variables. Results with p ≤ 0.05
were considered statistically signiﬁcant. The calculations
were made with the aid of the Graph Pad Prism (version 5.0)
software.Results
At disease onset, YORA patients (n = 111) were aged 32–58
(median = 45, IQR = 39.0–51.0) years; and EORA patients (n = 62)
were aged 60–83 (median = 63.0, IQR = 60.7–70.0) years. In EORA
group, the disease duration time was 1–16 (median = 3.0;
IQR = 1.0–6.5) years; and in YORA group, the disease duration
time was 1–13 (median = 5.0; IQR = 2.0–8.0) years (p = 0.21). In
Table 1, one can observe the comparison between these two
groups regarding demographic, serological and clinical char-
acteristics; it is worth noting the difference found for gender,
HAQ and RF between the groups. In EORA group there were
41.6% patients with low activity or remission by DAS 28 (<3.2)
as opposed to 38.7% in YORA group (p = 0.85). As regards the
use of medications, no difference was found between groups,
as can be seen in Table 2.
Discussion
The results of this study demonstrate that EORA in Brazil is
more  common in male individuals, and that patients with this
form of RA have better HAQ that of patients with YORA with
the same disease duration. The ﬁnding that males are more
affected in older age groups is a fact already widely recognized
in the literature.1,15 The Norfolk Arthritis Register,11 i.e. the
English arthritis registry, shows that the incidence of RA in
men  gradually increases with age, while in women it increases
from 45 years, reaching a plateau at 75 years, from which the
incidence starts to decline. Bajocchi et al.16 described a gender
distribution ratio of 1.5–2 women to 1 man  in the elderly versus
4–4.5 women for 1 man  in younger people.
It was also observed in the present study that the functional
state measured by HAQ had lower values in elderly individu-
als. This fact is interesting and is opposed to the idea that olderrthritis in elderly and young patients. Rev Bras Reumatol. 2016.
people, despite whether or not suffering from a rheumatic
disease, may show functional impairment related to the weak-
ness inherent to older people. This can be explained, if a higher
disease severity is ascribed to YORA. Pease et al.17 reported
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Table 2 – Comparison of treatments used in patients with elderly onset rheumatoid arthritis (EORA) versus young onset
rheumatoid arthritis (YORA).
EORA
n = 62
YORA
n  = 111
p
Corticosteroid use (number of patients) 48/62 (77.4%) 85/103 (82.5%)
Dose of corticosteroid mg/day (prednisone or
equivalent)
2.5 and 20.0
Median = 10.0
IQR = 5.0–10.0
2.50–20.00
Median = 5.0
IQR = 5.0–10.0
0.17
Methotrexate 49/62 (79.0%) 82/105 (78.0%) 0.88
/62 (5
/62 (1
62 (6.
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hat patients with EORA had a better prognosis and achieved
asier and faster remission. On the other hand, a Spanish
tudy18 shows that patients with elderly onset rheumatoid
rthritis have worse functional and anatomical indexes versus
orresponding younger subjects. Data from this study favor
he concept that RA in the elderly is not a more  serious condi-
ion than in young subjects. However, Naz et al.19 showed that
lder age at the time of diagnosis is associated with increased
ardiovascular mortality, suggesting the need for an aggres-
ive treatment to avoid premature death.
Tutuncu et al.7 investigating prescribing habits of 192
heumatologists, describe that patients with EORA receive
ess treatment than those with YORA, despite an identical
uration of disease and comparable activity and severity. As
lready mentioned, older people have more  co-morbidities,
re at higher risk of polypharmacy and are subject to a higher
revalence of side effects by changes in drug pharmacody-
amics and pharmacokinetics.1,2 The recognition that RA is
 disease with a poor prognosis and that the control of the
nﬂammatory process impacts decisively on functional capac-
ty and survival of the patient, may have been responsible for
 change of attitude toward this age group in recent years. In
his study, we  could not detect differences in the use of drugs
n the two disease onset ranges, showing that currently the
ggressiveness in treatment does not vary according to the
ge of onset, and a similar control of inﬂammation, measured
y DAS 28, was obtained in both populations.
This study has some limitations. Due to the retrospective
ature of the study, it was not possible to access certain infor-
ation such as, for instance, the prevalence of secondary
jögren syndrome in both groups. Interestingly, we observed
 lower tendency for investigation of such kind of symptoms
n the older age group. It may be that such fact occurred
y attributing the sicca symptoms to their own age, or to
he concomitant use of other drugs, such as diuretics and
ntidepressants, common in older people. Another limitation
s the fact that only individuals who already have completed
our ACR (1987) classiﬁcation criteria for RA were included.
his choice was made because this is a retrospective study;
hus, the quality of information is dependent on the correct
ompletion of medical records. It is therefore important to
tress that the above ﬁndings are only valid for this type of
atients. Subjects with atypical forms of RA, such as thosePlease cite this article in press as: Horiuchi AC, et al. Rheumatoid a
http://dx.doi.org/10.1016/j.rbre.2015.06.002
ith preferential involvement of large joints, polymyalgia
heumatica-like forms and RS3PE have not been studied. On
he other hand, this same selective process allowed the inclu-
ion of individuals with a more  accurate diagnosis, with the1.6%) 44/105 (41.0%) 0.22
6.1%) 28/105 (26.2%) 0.72
4%) 6/104 (5.7%) 1.00
exclusion of other diseases that, in the elderly, may simulate
RA, such as microcrystalline diseases. The strategy used for
our inclusion criterion of patients may also have been respon-
sible for the higher prevalence of positive RF in EORA found in
this study, since most authors have described this variable as
being lower than that found in young subjects.1,11 Although
the literature mentions that healthy elderly are likely to have
a higher prevalence of RF, a fact attributed solely to age, it is
interesting to note that this ﬁnding could not be proven in a
study of 336 healthy patients in our region.20 Therefore, the
higher prevalence of this autoantibody found in this study
cannot be justiﬁed by immune system changes associated
with the aging process. Furthermore, it is worth noting that
the cutoff point used for deﬁning EORA in this study was 60
years,1 which makes this population somewhat younger and
less subject to immunosenescence than that from other stud-
ies, where the cutoff point of 65 years was adopted.8
Moreover, in this study a comparison group matched for
disease duration was included, which allowed a more  realistic
analysis of the effects of the disease on the functional capacity
of the different groups.
An interesting observation was the ﬁnding of a trend
toward the appearance of interstitial pneumonitis in EORA
individuals. Although this extra-articular manifestation was
not associated with age at disease onset, it has been found
more frequently in male individuals21 who, in turn, are more
common in EORA groups. One should take into account that
this ﬁnding may be inﬂuenced by the fact that this study
was performed in a tertiary center, with a heavier referral of
patients with more  severe disease.
In conclusion, it can be said that, in our region, patients
with EORA have higher prevalence of male individuals and
that, despite equal treatment and control of inﬂammatory
activity in both groups, patients with YORA have a worse func-
tional performance.
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